Incyte Patent-Cliff Exposure & CMS Drug Spending Portfolio
Incyte (Wilmington, DE): 6 reconciled FDA prescription therapies (98.6% 2025 to 2030 cliff risk), $2.51B 2024 CMS Part D & Medicaid spend, and 18 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | Wilmington, DE |
| Reconciled FDA Portfolio Therapies | 6 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 98.6% |
| Primary Portfolio LOE Date | 2029-01-01 |
| 2024 CMS Total Public Spend | $2.51B |
| 2024 Medicare Part D Spend | $2.22B |
| 2024 Medicaid Spend | $291.2M |
| California HCAI SB 17 Filings | 18 WAC filings (max 20.0% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Incyte across sibling Meru public-data platforms.